Contact:
Karen Whelan, Public Relations & Practice Marketing Specialist
508-787-1461
kwhelan@optos.com
Optos to Participate in Hawaiian Eye 2007
1/12/2007
MARLBOROUGH, MA, January 12, 2007 – Optos, a leading medical technology company for the design, development, manufacturing, and marketing of retinal imaging devices, will be an exhibitor at the Hawaiian Eye 2007 Meeting on January 14-19, 2007 in Kauai, HI.
Optos representatives will be at its booth, #205, throughout the meeting to discuss its newest technology – optomap® fa Dynamic Ultra-widefield Angiography – designed to offer advanced diagnostic retinal imaging through the provision of widefield fluorescein angiography. Optos encourages attendees to stop by the booth to receive a complimentary optomap® Retinal Exam with the Panoramic200 Scanning Laser Ophthalmoscope. Attendees will also be updated on the technical and clinical components of the new system, and receive a sneak-preview of the newest software, Version 2.3, available to Partners shortly.
"The Optos Angiography System (P200MA) is a revolutionary retinal imaging tool that provides a unique view of the peripheral retinal circulation in diseases such as diabetic retinopathy and vein occlusion. I believe that it will provide a new understanding of the role of peripheral ischemia in the pathogenesis and successful treatment of these and related disorders,” said Carmen A. Puliafito M.D.
Attendees are encouraged to visit Optos’ booth as well as attend a session on January 19th at 7:35 am, by esteemed speaker, Carmen Puliafito, M.D., M.B.A, Bascom Palmer Eye Institute, University of Miami, to learn more about the Ultra-widefield Angiography system. The session is titled “Panoramic Widefield Fluoroscein Angiography in Retinal Vascular Diseases.”
Note to Editors
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.
The Company has recently gained regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. The P200MA is aimed at the specialist ophthalmic and medical as opposed to the primary care market. It is designed to produce an angiographic retinal image called optomap® fa that supports medical procedures by providing enhanced diagnostic, monitoring and treatment capabilities. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Optos estimates that its P200 device is targeting a recurring US$2 billion market opportunity. As at 30 September 2006 Optos had 232 employees serving more than 2,500 customers in the Company’s existing markets, currently the USA, Canada, UK and Germany. Optos plc is headquartered in Dunfermline, Scotland and was admitted to the Main Market of the London Stock Exchange on 15 February 2006 trading under the symbol OPTS.